Carriers of the MSH6 mutation were at higher risk for colorectal and endometrial cancers and any cancer associated with Lynch syndrome by age 80. Mutations in MSH6 account for 10% to 20% of Lynch ...

MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. GENETICS in MEDICINE, 2018; DOI: 10.1038/gim.2017.254 ...

This case report centers on a young girl with biallelic MSH6 mutations who underwent allogeneic bone marrow transplantation, panproctocolectomy, and chemotherapy.

It is known that mutations in MSH6 account for 10%-20% of Lynch syndrome, which causes colorectal and other cancers, but less is know about the cumulative cancer risks for mutation carriers. In ...

Methods: MSH6 exon 9 insertion and deletion mutations were analyzed in 2,660 colorectal cancer (CRC) cases and 3,270 healthy controls of Ashkenazi Jewish (AJ) descent from population-based and ...

The MMR IHC Panel PharmaDx (Dako Omnis) is used to identify loss of function in mismatch repair proteins and inform the treatment of colorectal cancer patients.

MSH2/MSH6 alterations were associated with a significantly higher TMB than MLH1/PMS2 across several cancer types. The MS alterations associated with MSH2/6 were tumor-type specific. This is an ASCO ...

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in ...

Cite this: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations - Medscape - Feb 01, 2007.